Posted by Michael Wonder on 22 Feb 2022
New PMPRB report shows significant consistency in public drug plan coverage across Canada for drugs subject to "Common Drug Review" process
22 February 2022 - The Patented Medicine Prices Review Board released today the third and final part in the Alignment Among Public Formularies in Canada series, which explores the current gaps and overlaps in Canadian public drug plan formularies.
This report compares formulary coverage across Canada's public drug plans for 307 medicines reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH)'s Common Drug Review process between 16 December 2003, and 30 June 2019.
